title: Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
abstract: After curative resection for gastric adenocarcinoma, 103 patients, all with positive nodes, were randomised so that 48 received adjuvant chemotherapy of epidoxorubicin (EPI) 75 mg m-2 on day 1, leucovorin (LV) 200 mg m-2 on days 1-3 and 5-fluorouracil (5-FU) 450 mg m-2 on days 1-3, every 21 days for 7 months, whereas the remaining 55 did not. During the first year of observation, 21 control patients (38%) and five treated patients had recurrences. After a follow-up period of 36 months, 12 of the treated patients (25%) and only seven controls (13%) were still alive. At that point, the median survival was 13.6 months for the 55 untreated patients and 20.4 months for the 48 treated patients, a significant difference. We found a survival advantage for patients treated with the EPI-LV-5-FU regimen and a consistent delay in the appearance of recurrent or metastatic cancer. Acute toxicity was mild and treatment was well accepted by all patients. There was no long-term toxicity or any cardiac toxicity. We conclude that this particular chemotherapy, administered shortly after gastric resection, improves survival rate in node-positive gastric cancer patients, even although final assessment of this particular adjuvant approach must await completion of the trial.
authors.affiliation: Institute of Internal Medicine, Oncological Day Hospital, University of Florence, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Neri
authors.forename: V
authors.initials: V
authors.lastname: de Leonardis
authors.forename: S
authors.initials: S
authors.lastname: Romano
authors.forename: F
authors.initials: F
authors.lastname: Andreoli
authors.forename: L M
authors.initials: LM
authors.lastname: Pernice
authors.forename: L
authors.initials: L
authors.lastname: Bruno
authors.forename: D
authors.initials: D
authors.lastname: Borrelli
authors.forename: A
authors.initials: A
authors.lastname: Valeri
authors.forename: S
authors.initials: S
authors.lastname: Fabbroni
authors.forename: C
authors.initials: C
authors.lastname: Intini
authors.forename: G
authors.initials: G
authors.lastname: Cini
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012008:Recurrence; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate; D013997:Time Factors
chemical_list: D015251:Epirubicin; D002955:Leucovorin; D005472:Fluorouracil